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Sepsis, manifested by systemic inflammatory response syndrome (SIRS), sep-
tic shock and multiple organ dysfunction syndrome (MODS), remains the lead-
ing cause ofmorbidity and mortality in critically ill patients. Despite advances
and our knowledge of sepsis, there remain clinical dilemmas that impact how
we treat patients. These clinical dilemmas include hypotension, cardiac dys-
function and altered oxygen consumption. There is increasing recognition that
treatment of these problems does not necessarily improve outcome. As we
improve our understanding of sepsis, there is increased recognition that
improvement in morbidity and survival will come not only from treating the
manifestations of sepsis but also the endogenous mediators responsible for the
development ofthese clinically important conditions. This manuscript discuss-
es the clinical dilemmas associated with sepsis, current therapy andfuture direc-
tions for managing sepsis.
INTRODUCTION
TheAmerican College ofChest Physicians and the Society ofCritical Care Medicine
published their definitions for sepsis and organ failure in 1992, definitions to which many
subscribe (Table 1) [1]. This definition of sepsis and organ failure correlates with the
development ofmorbidity (multiple organ dysfunction syndrome [MODS]b) and mortali-
ty [2].
The incidence of sepsis is increasing in the United States and presumably in other
countries. Data from a decade ago demonstrate that the incidence rose 139 percent over a
nine-year interval [3], an increase that is thought not only to be due to an increased
improvement in reporting but also to an increase in predisposing factors, i.e., an aging
population, presence of comorbidities (human immunodeficiency virus), transplantation
(immunosuppression) and the increased use of invasive devices leading to iatrogenic
infections. A more recent study indicates that the incidence of sepsis is even higher than
that reported by the Morbidity and Mortality Weekly Report [3]. The incidence may be
two to three times higher, at approximately 400 to 500 patients per 100,000 population per
year [4].
Despite improved understanding of the pathogenesis of sepsis and of new therapies,
the mortality notonly remains high but is thought to be increasing [5]. It is imperative that
current therapies ofsepsis be assessed and evaluated and new treatments designed. In this
context, it is clear that there are a number of dilemmas that face the healthcare provider
when caring for a patient with systemic inflammatory response syndrome (SIRS), sepsis
or septic shock.
a To whom correspondence should be addressed: Michael J. Murray, M.D., Ph.D., Mayo Clinic,
200 First Street, SW, Rochester, MN 55905. Tel.: (507) 255-3280; Fax: (507) 255-4267; E-mail:
murray.michael@mayo.edu.
b Abbreviations: MODS, multiple organ dysfunction syndrome; SIRS, systemic inflammatory
response syndrome; SVR, systemic vascular resistance; LVEDV, left ventricular-end diastolic vol-
ume; ICU, intensive care unit.
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CLINICAL DILEMMAS
Hypotension
A decrease in blood pressure is one ofthe characteristics ofGram-negative sepsis. In
animal models ofsepsis, after an intravenous injection ofendotoxin or live bacteria, there
is actually an increase in blood pressure initially, an increase that lasts for approximately
20 to 30 minutes before the animal becomes hypotensive. This increase and subsequent
decrease in systemic vascular resistance (SVR) is thought to be secondary to the interac-
tion ofa number ofendogenous vasoactive compounds [6], often on the vascular endothe-
lium [7]. At the arteriolar level, arterioles are maximally vasodilated, others vasocon-
stricted, in an attempt to elevate perfusion pressure. In fact, this is one ofthe paradoxes of
hypotension. A number of shunts through the vascular beds of organs are open so that if
blood flow to that organ is measured, it can be normal to high. When one examines cap-
illary blood flow, though, evidence of vasoconstriction and lack of perfusion exist. The
dilemma then is how to augment flow using a vasoconstrictor that does not worsen capil-
lary perfusion but raises the SVR within those vessels that are vasodilated and shunting
blood through the organ.
Not all studies have identified alterations in organ blood flow in sepsis. Finley and
colleagues found that the average muscle blood flow was greater in septic than nonseptic
patients as was skeletal capillary muscle blood flow [8]. Ifthe latter is truly the case, then
the defect in tissue oxygenation, if such a defect exists, is not secondary to a decrease in
flow, but may be related to a block in oxygen transport either within the cell or at some
level within the mitochondria. The conundrum the physician faces is whether to increase
blood pressure or increase flow; ifthe findings ofFinley and colleagues are reliable, then
no increase in flow or pressure will alter the potential block at the mitochondrial level.
Hyperdynamic cardiacfunction
Historical accounts of septic shock describe a warm and cold phase of septic shock:
the "warm phase" characterized by an increase in cardiac output. Two decades ago, the
prevailing beliefwas that when patients first became septic, they were in a hyperdynamic
phase manifested by high cardiac outputs, increased peripheral perfusion and wanning of
the extremities and skin. It was only later, in the irreversible phase ofshock, that patients
Table 1. Definitions.
Systemic inflammatory Activation ofthe immune system by an infectious agent with release
response syndrome ofcytokines and anumberofvasoactive substances. Theirresponse is
(SIRS) characterized by alterations in temperature (>380C or <360C), elevat-
ed heart rate (>90beats/min), tachypnea (>20 breaths/min) and leuko-
cytosis (>12,000/m3).
Sepsis Sepsis is the SIRS with the presence of an identifiable infectious
source-be it an abscess or an infected lime. The same criteria as in
sepsis applies, but a recognized infectious source must be present.
Severe sepsis is sepsis associated with the presence oforgan dysfunc-
tion.
Septic shock Septic shock is a severe sepsis with presence ofhypotension (systolic
blood pressure <90 mmHg or a >44 mmHg decrease from baseline)
despite adequate filling pressure (pulmonary artery occlusion pres-
sure at 12 to 18 mmHg).
486Murray: Sepsis: Clinical dilemmas
became cool, acidosis developed and cardiac output fell, to the point that it was inadequate
to perfuse and oxygenate the extremities. This was usually a premorbid event.
Parker and colleagues were surprised when they studied 28 patients with septic shock
to find that the majority had evidence ofmyocardial dysfunction, despite the fact that the
majority also had high cardiac outputs [9]. This same group ofinvestigators believed that
the myocardial depression was related to a circulating myocardial depressant factor [10].
They also speculated that the myocardial dysfunction was actually aprotective event. In a
subsequent analysis oftheir 20 patients, they found that those patients who were survivors
had left ventricular dilation, and areduction in ejection fraction, butmaintenance ofstroke
volume. These same patients had high cardiac outputs due to an associated tachycardia.
Nonsurvivors did not have an increase in their left ventricular end-diastolic volume
(LVEDV). Parker and colleagues at the National Institutes ofHealth speculated that in the
survivors, the increase in LVEDV with a decrease in stroke volume decreased the work-
load on the left ventricle and was somehow protective. Survivors eventually decreased
their LVEDV to normal, with a return to normal in their ejection fraction, with stroke vol-
ume staying essentially the same. Nonsurvivors, however, may have maintained their
LVEDV, their stroke volume and the ejection fraction at the expense of an increase in left
ventricular work (Figure 1) [11].
Oxygen deliveryloxygen consumption
In the 1960s, investigators recognized that there was defective oxygen consumption
in septic shock [12]. More recently, with the understanding of what was happening at the
ACUTE PHASE OF SEPTIC SHOCK
Stroke Volume = 50mI
U Ejection Fraction = 200ml-150mI =25%
200m1
Left Ventricular Left Ventricular
End Diastolic End Systolic
Volume = 200ml Volume = 150ml
RECOVERY PHASE OF SEPTIC SHOCK
Stroke Volume = 50ml
Ejection Fraction= 100mI - 50mI =50%
Left Ventricular Left Ventricular
End Diastolic End Systolic
Volume = 100mI Volume = 50ml
Figure 1. A schematic representation of the reversible myocardial depression seen in the sur-
vivors ofseptic shock. Reprinted with permission from: Parker, M.M., Shelhamer, J.H., Bacharach,
S.L., Green, M.V., Natanson, C., Frederick, T.M., Damske, B.A., and Parrillo, J.E. Profound but
reversible myocardial depression in patients with septic shock. Ann. Intem. Med. 100:488, 1984.
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capillary level in terms of blood flow, investigators speculated that improving oxygen
delivery might increase survival in septic patients. Support for this hypothesis was gener-
ated from studies conducted by Shoemaker and colleagues in several groups of patients
[13]. A recent consensus conference concluded that although there was a general belief
that whole body and organ-specific oxygen availability were important to monitor in sep-
sis, there were no good data to support the concept that titrating therapy to specific hemo-
dynamic and oxygen transportvalueimproves outcome [14]. Part oftheproblem in under-
standing the relationship of oxygen delivery to oxygen consumption may come from the
factthatthere is mathematicalcoupling ofdata [15]. Incalculating therelationshipofoxy-
gen consumption to oxygendelivery, it is important to understand thatcommonly the Fick
equation is used to help calculate both variables, i.e., the cardiac index as measured by
thermodilution techniques using a pulmonary artery catheter, is used in both the data on
the abscessa and the ordinate. Perhaps a better way to assess a relationship is to use indi-
rect calorimetry to measure oxygen consumption and the Fick equation to measure oxy-
gen delivery. Under those circumstances, if a relationship exists, then the contribution of
mathematical coupling of data would be eliminated [15].
TREATMENTS
Most studies of promising therapies to treat septic shock have failed to demonstrate
an improvement in outcome [16-18]. As already stated, a recent consensus conference
found that there were little data demonstrating an improvement in outcome for many of
thetherapies that are currently used intreatingpatients with sepsis [14]. Prevention ofsep-
sis from iatrogenic injuries and nosocomial infection is, therefore, extremely important
[19]. In fact, simple hand washing in the intensive care unit (ICU) and attention to detail
in handling urinary catheters, pulmonary hygiene, and use of parenteral nutrition only
when necessary, is as or more important than any other modality in decreasing the inci-
dence of sepsis and subsequent mortality in the ICU [20].
Although a great deal ofattention in managing patients with sepsis is devoted to dis-
cussions of the appropriate use of antibiotics, fluid therapy and inotropes, Natanson and
colleagues atthe National Institutes ofHealth demonstrated in anelegant study in acanine
model that these interventions, even when carefully titrated, did not improve survival of
septic animals [21]. Septic dogs given notherapy had a 100 percentmortality at fourdays,
animals given antibiotics alone had a 90 percent mortality, and animals given cardiovas-
cular support to include fluid therapy and inotropes after volume resuscitation, likewise,
had 90 percent mortality. It was a combination of antibiotics and appropriate cardiovas-
cular support that lead to improvement in survival to 50 percent. We currently have some
of the most potent, well-designed antibiotics available and yet the mortality rate is still
high. Likewise, we understand the adrenergic mechanisms that are active during septic
shock. Therapy to impact outcome and improve survival in patients with septic shock,
however, has failed despite studies of multiple new therapies. When choosing antibiotic
therapy for patients with sepsis and who are non-neutropenic, there is good evidence that
a single agent is probably as good as combination therapy [22]. Institution of appropriate
antibiotic therapy early in the course of sepsis is important, but it is ethically impossible
to demonstrate benefit to antibiotic therapy in the majority ofpatients with sepsis and sep-
tic shock.
Though a decrease in SVR and hypotension correlates well with mortality [23],
improvement in SVR and in blood pressure does not necessarily correlate with an
improvement in outcome. Hypotension is probably a marker of severity of illness and of
mortality, but not necessarily the causative factor [24]. However, a long-standing tenet of
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therapy for septic shock is to increase SVR andraise bloodpressure using catecholamines.
Unfortunately, blood pressure is often refractive to vasoconstrictor therapy, primarily
because of down regulation of the adrenergic receptors and of the interaction of other
endogenous mediators. Using nitric oxide synthase inhibitors, it is possible to improve
blood pressure, but no one has yet demonstrated an improvement in outcome. A great deal
of attention has been given to choosing appropriate inotropes and vasopressors in septic
shock [25]. We already have potent inotropes and vasopressors, improving outcome will
likely not come from the development ofnew inotropes or vasopressors. In patients with
profound hypotension, if vasoconstrictor therapy is used, norepinephrine with its alpha-
adrenergic effects is better than beta-adrenergic agents [26]. But to avoid excessive vaso-
constriction, it is probably best to use a combination ofnorepinephrine and an agent such
as dopamine, which will maintain renal perfusion and urine output. There is evidence that
if a beta-adrenergic agent is used, that dobutamine works as well as any other agent [27].
Many of the manifestations of sepsis and septic shock are markers ofthe severity of
comorbid disease and not the causative factor in mortality. Since these effects come not
necessarily from bacteria themselves or from bacteria-derived products but from endoge-
nous mediators, new therapies are targeted at manipulating these endogenous mediators
[28]. It is naive to assume though that there is a single agent or a "magic bullet" that will
improve outcome [29]. A better understanding ofthe interplay between these endogenous
mediators and the host organism is important, and perhaps a multimodel therapy will ulti-
mately be the treatment that improves outcome in patients with a systemic reaction to an
infectious agent. These issues are discussed in other articles in this issue.
CONCLUSION
The clinician managing the patient with SIRS/sepsis/septic shock is faced with a
number ofclinical dilemmas. The patient may be hypotensive, but raising blood pressure
does not necessarily improve perfusion in peripheral vascular beds. Likewise, though the
patient may have an elevated cardiac output, this does not necessarily imply'that cardiac
function is normal or adequate. Improving perfusion pressure and cardiac output, howev-
er, which will improve oxygen delivery and in some circumstances oxygen consumption,
does not necessarily lead to an improvement in survival. However, if one ignores the car-
diac dysfunction and hypotension, certainly mortality can be in excess of 50 percent.
When managing patients in the hospital or in an ICU environment, it is important to
avoid iatrogenic injury and to prevent infection, particularly in those who are at the
extremes of age and who are immunocompromised for whatever reason. The appropriate
antibiotics given early in the course ofthe infection, fluid therapy (either colloid or crys-
talloid) to improve left ventricular filling pressure, and inotropes and vasoconstrictors
when judged to be clinically necessary are important in managing septic patients.
However, even with the best ofcare, the mortality rate remains approximately 50 percent.
Improvement in outcome will most likely depend on a better understanding ofthe patho-
physiology of the endogenous mediators that underlie the systemic response to infection
and appropriate interventions, perhaps more than one, to nullify or modify this over-exu-
berant release ofendogenous cytokines and inflammatory agents.
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